Monogram Residential Trust In

To hear Wall Street tell it, AbbVie Inc. drove right into a ditch last month.

Here's the thing. The company announced results of a Phase 2 trial on March 22 that were disappointing but hardly fatal. The results mean AbbVie won't seek fast-track approval for its promising antibody-drug conjugate, Rova-T, but it still expects to be able to take it to market in the near future.

Wall Street overreacted – no surprise there – and AbbVie shares lost 15% in three sessions.

Here's the thing. Wall Street's overreaction to AbbVie's disappointing U.S. Food and Drug Administration trial results weren't the only reason for its share-price plummet.

You see, though it shouldn't be, biotech is in the dog house – and investors are primed to punish stocks in the sector for just about anything.

But what you don't hear much about is the fact that the industry is about to bust out.

That's because biopharma companies are ready to release several potential blockbuster drugs – drugs with potential yearly sales of $1 billion – over the next few months.

I've identified three specific "Biotech Blockbusters" that could do even better than that. So, I'll show you those.